Braveheart Bio, Inc. · NASDAQ Global · priced Aug 6, 2026 · $383M raised · Over $250M
Price since listing
- Hype
- Distribution
- Lock-up window
- Valley
- Accumulation
- Recovery
Volume bars are coloured by lifecycle phase. Markers: lock-up and early release (orange), earnings releases (E), follow-on offerings (F), research signals (rule id and signal; arrow up = buy signal, arrow down = sell or short signal, or sell signal for deals under $50M). Current phase: Distribution.
Performance since the IPO
- BRVE
- S&P 500 (SPY)
- Typical IPO over $250m
- Middle 50% of those IPOs
BRVE measured from its offer price; S&P 500 from the first trading day. The typical-IPO line is the median of 340 over $250m IPOs from 2014–2025, by trading day.
Company
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Fr…
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Employees
- 49
- Market cap
- $1.9B
- Website
- www.braveheart.bio
From the prospectus
- Lock-up
- 180 days
- Early release on earnings
- No
- Price-based early release
- No
- Staggered release
- No
- Float sold in IPO
- 29%
- Locked shares per share sold
- 2.4×
- Backed by
- Mixed investors
- Lead underwriters
- Goldman Sachs & Co. LLC, Jefferies LLC, TD Securities (USA) LLC, Stifel, Nicolaus & Company, Incorporated
- Dual-class shares
- No
- Controlled company
- No
- Foreign private issuer
- No
Extracted from the final prospectus on SEC EDGAR.
Returns vs offer, compared with 135 IPOs over $250m
| Horizon | BRVE | Peer median | Peers below offer |
|---|---|---|---|
| Day 1 | +65.6% | +12.8% | 24% n=135 |
| Day 20 | +49.7% | +11.6% | 30% n=133 |
| Day 60 | +17.7% | +6.3% | 47% n=129 |
| Day 120 | — | -4.6% | 54% n=106 |
| Day 180 | — | -4.1% | 52% n=89 |
Research signals
No rule has triggered for this IPO.
Rules frozen as v1; signals dated from Oct 29, 2026 are live, earlier ones show what the frozen rules would have flagged. See methodology.
Past figures cover all 4,312 signals the published frozen v1 rules produce on 2014–2025 IPOs, close to close over each signal's holding period. Returns start at the close of the signal session; signals are published after that close, so the first price available to a reader is the next session's. Only 1,192 of 2,368 operating-company IPOs from those years have usable Yahoo Finance price data; most of the rest no longer trade under their IPO ticker (delisted, acquired or renamed), so the figures probably understate declines. These are hypothetical results, not trades: the rules were selected on these same years with the benefit of hindsight, so the figures likely overstate what live signals will do. The live track record is the real test. Trading costs and borrow fees are not included. Past results do not predict future results.
Research signals only, not investment advice. Lock-up terms come from prospectuses; prices from Yahoo Finance and may be delayed or wrong.